Corey Berlin, MD
Endocrinology, Diabetes & Metabolism · Raleigh, NCNPI 1154399418
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $601,486 of the $741,738 with a category attached, or 81.1%. 60 manufacturers reported payments, led by Lilly USA, LLC at 36.5% of the total. Reporting peaked in 2019 at $212,306 and has fallen 73.8% since, to $55,689 in 2025. Among endocrinology, diabetes & metabolism clinicians in NC with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 2,438 payments — averaging $304.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$271K
- Novo Nordisk$222K
- Boehringer Ingelheim$72K
- Amarin Pharma, Inc.$50K
- Johnson & Johnson$36K
- AstraZeneca$33K
- plus $58K from 54 others
What the payments were for
- Consulting fees$2,9250%
- Speaking & faculty fees$601,48681%
- Travel & lodging$95,44613%
- Food & beverage$41,6556%
- Education$2250%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$741,738 in reported general payments places this provider in the 95th percentile of 232 endocrinology, diabetes & metabolism providers in North Carolina.
See all endocrinology, diabetes & metabolism providers in North Carolina →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 351 | $460,489 |
| MounjaroTirzepatide | 316 | $362,664 |
| JardianceEmpagliflozin | 177 | $173,884 |
| RybelsusSemaglutide | 105 | $103,283 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 120 | $100,113 |
| Tresiba Flextouch U-100Insulin Degludec | 145 | $94,243 |
| Tresiba Flextouch U-200Insulin Degludec | 104 | $92,653 |
| TrulicityDulaglutide | 58 | $83,648 |
| ProliaDenosumab | 48 | $83,282 |
| TymlosAbaloparatide | 27 | $71,097 |
| AfrezzaInsulin Regular, Human | 28 | $58,206 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 72 | $50,643 |
| FarxigaDapagliflozin Propanediol | 69 | $45,432 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 33 | $40,925 |
| VascepaIcosapent Ethyl | 59 | $36,445 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus, Fiasp, Novolog | $221,596 | $585,334500 claims |
| Lilly USA, LLCMounjaro, Trulicity, Lyumjev, Humalog | $270,968 | $493,660431 claims |
| Boehringer IngelheimJardiance, Synjardy Xr, Synjardy, Tradjenta | $72,239 | $311,277347 claims |
| AmgenProlia | $1,809 | $83,28248 claims |
| Radius Health, Inc.Tymlos | $6,922 | $71,09727 claims |
| Mannkind CorporationAfrezza | $8,487 | $58,20628 claims |
| AstraZenecaFarxiga | $33,236 | $45,43269 claims |
| AbbVieSynthroid | $748 | $28,412428 claims |
| Johnson & JohnsonInvokamet | $35,835 | $19,50024 claims |
| Clarus Therapeutics Inc.Jatenzo | $56 | $17,40917 claims |
| Esperion Therapeutics, Inc.Nexlizet | $1,607 | $15,13921 claims |
| Antares Pharma, Inc.Xyosted | $596 | $11,28212 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 232 endocrinology, diabetes & metabolism providers in North Carolina.
Other endocrinology, diabetes & metabolism in Raleigh
- Denis BeckerRaleigh$459K
- Elizabeth HoltRaleigh$167K
- Julia Warren-UlanchRaleigh$31K
- Bhairavi SheshadriRaleigh$28K
- Glenn StallRaleigh$9K
- Mark WarrenGreenville$915K
- Thomas OconnellBurlington$805K
- Michael FavoritoWilmington$723K
- Stephen SouthGreensboro$624K
- Richard DoddAsheville$526K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.